EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost-effectiveness analysis of sacituzumab tirumotecan as second-line therapy for EGFR-TKI–resistant, EGFR-mutated advanced NSCLC in China

Jing He, Jialin Yu, Ruixuan Liu, Qing Yang

Expert Review of Pharmacoeconomics & Outcomes Research · 03.07.2026 · 26 (6) · 813-822

DOI: 10.1080/14737167.2026.2691180 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 10.07.2026. Verfasst von Jing He und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansCost-Benefit AnalysisChinaErbB ReceptorsCost-Effectiveness AnalysisDrug Resistance, NeoplasmMutationQuality-Adjusted Life YearsAntineoplastic Combined Chemotherapy ProtocolsPemetrexedProtein Kinase Inhibitors

Stichwörter der Autor:innen

Cost-effectivenessEGFR mutationnon-small cell lung cancersacituzumab tirumotecansecond-line therapy

Substanzen

ErbB ReceptorsEGFR protein, humanPemetrexedProtein Kinase Inhibitors

Autor:innen und Institutionen

  • School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
  • School of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

He, J., Yu, J., Liu, R., & Yang, Q. (2026). Cost-effectiveness analysis of sacituzumab tirumotecan as second-line therapy for EGFR-TKI–resistant, EGFR-mutated advanced NSCLC in China. Expert Review of Pharmacoeconomics & Outcomes Research, 26(6), 813-822. https://doi.org/10.1080/14737167.2026.2691180

Vancouver

He J, Yu J, Liu R, Yang Q. Cost-effectiveness analysis of sacituzumab tirumotecan as second-line therapy for EGFR-TKI–resistant, EGFR-mutated advanced NSCLC in China. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(6):813-822. doi:10.1080/14737167.2026.2691180

BibTeX
@article{He2026,
  author = {He, Jing and Yu, Jialin and Liu, Ruixuan and Yang, Qing},
  title = {Cost-effectiveness analysis of sacituzumab tirumotecan as second-line therapy for EGFR-TKI–resistant, EGFR-mutated advanced NSCLC in China},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  volume = {26},
  number = {6},
  pages = {813--822},
  doi = {10.1080/14737167.2026.2691180}
}
Kostenlos starten →